Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: A subgroup analysis of the inclusive trial

Journal of the National Medical Association

Volumn 101, Issue 4, 2009, Pages 300-307

  Chrysant, Steven G ^a   Neutel, Joel M ^b   Ferdinand, Keith C ^c  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b Orange County Research Center   (United States)

^c Association of Black Cardiologists   (United States)

Author keywords

Drugs; Hypertension

Indexed keywords

HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; PLACEBO;

ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; METABOLIC SYNDROME X; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE DIFFERENCE; SEX DIFFERENCE; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

EID: 66949135087     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)30876-2     Document Type: Article

References (50)

1. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
2. Franklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension. 2001;37:869-874.
3. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension. 1995;26:60-69.
4. US Census Bureau. The 65 years and over population: 2000. Washington, DC: US Census Bureau;2001. www.census.gov/prod/2001pubs/c2kbr01- 10.pdf. Accessed 02/01/07.
5. US Census Bureau. International Data Base (IDB) Web site. 2006. www.census.gov/ipc/www/idb/. Accessed 02/01/07.
6. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991:265:3255-3264.
7. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA. 1997;278:212-216.
8. Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA. 1999:282:539-546.
9. American Diabetes Association. Standards of medical care in diabe- tes-2007. Diabetes Care. 2007;30(Suppl 1):S4-S41.
10. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension. The Taskforce for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hyperfens. 2007:25:1101-1187.
11. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003; 163:525-541.
12. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/lnternational Society of Hypertension (ISH) statement on management of hypertension. J Hyper- tens. 2003;21:1983-1992.
13. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;345:479-486.
14. Lloyd-Jones DM, Evans JC, Larson MG, et al. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension. 2000;36:594-599.
15. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49:69-75.
16. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339:1957- 1963.
17. Hyman DJ, Pavlik VN, Vallbona C. Physician role in lack of awareness and control of hypertension. J Clin Hyperfens (Greenwich]. 2000:2:324-330.
18. Neutel JM, Smith DH. Improving patient compliance: a major goal in the management of hypertension. J Clin Hyperfens (Greenwich]. 2003:5:127- 132.
19. Kaplan NM. What is goal blood pressure for the treatment of hypertension? Arch IntemMed. 2001:161:1480-1482.
20. Vardan S, Mookheijee S. Perspectives on isolated systolic hypertension in elderly patients. Arch Fam Med. 2000;9:319-323.
21. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993:328:914-921.
22. Materson BJ, Reda DJ, Cushman WC. Department of Veterans'Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hyperfens. 199S;8:189-192.
23. Waeber B, Burnier M, Brunner HR. Compliance with antihypertensive therapy. Clin Exp Hyperfens. 1999;21:973-985.
24. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002;62:443-462.
25. Volpe M. Treatment of systolic hypertension: spotlight on recent studies with angiotensin II antagonists. J Hum Hyperfens. 2005:19:93-102.
26. Stergiou GS. Angiotensin receptor blockade in the challenging era of systolic hypertension. J Hum Hyperfens. 2004; 18:837-847.
27. Chrysant SG. Vascular remodeling: the role of angiotensin-converting enzyme inhibitors. Am Heart J. 1998;135:S21 -S30.
28. Kochar M, Guthrie R, Triscari J, et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hyperfens. 1999;12:797-805.
29. Howe P, Phillips P, Saini R, Kassler-Taub K. The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Clin Exp Hyperfens. 1999;21:1373-1396.
30. Neutel JM, Franklin SS, Lapuerta P, et al. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hyperfens. 2008;22:266-274.
31. Neutel JM, Saunders, E, Bakris GL, et al. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/HCTZ in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Cfin Hyperfens (Greenwich}. 2005:7:578-586.
32. Neutel JM, Franklin SS, Oparil S. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hyperfens [Greenwich]. 2006;8:850-857.
33. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel ill). JAMA. 2001;285:2486-2497.
34. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd edn. John Wiley & Sons: New York, NY; 1981.
35. Rosenstock J, Rossi L, Lin CS, et al. The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients nonresponsive to hydrochlorothiazide alone. J Clin Pharm Ther. 1998:23:433-440.
36. Raskin P, Guthrie R, Flack J, et al. The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide. J Hum Hyperfens. 1999;13:683-687.
37. Ofili EO, Ferdinand KC, Saunders E, et al. Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. J Natl Med Assoc. 2006:98:618-626.
38. Sowers JR, Neutel JM, Saunders E, et al. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich). 2006;8:470-480.
39. Papademetriou V, Farsang C, Elmfeldt D, et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am CollCardiol. 2004:44:1175-1180.
40. Manolis AJ, Reid JL, de Zeeuw D, et al for the ARAMIS Study Group. Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study:, efficacy and safety of telmisartan 20,40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo. J Hyperfens. 2004:22:1033- 1037.
41. Wing LM, Arnolda LF, Upton J, et al. Candesartan and hydrochlorothiazide in isolated systolic hypertension. Blood Press. 2003; 12:246-254.
42. Neutel JM, Weir MR, Moser M, et al. The effects of candesartan cilexetil in isolated systolic hypertension: a clinical experience trial. J Clin Hypertens (Greenwich). 2000;2:181-186.
43. Kjeldsen SE, Lyle PA, Kizer JR, et al for the LIFE Study Group. The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. J din Hypertens (Greenwich). 2005:7:152-158.
44. Volpe M, Junren Z, Maxwell T, et al. Comparison of the blood pressure- lowering effects and tolerability of Losartan- and Amlodipine-based regimens in patients with isolated systolic hypertension. Clin Ther. 2003:25:1469- 1489.
45. Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.JAMA.2002;288:1491-1498.
46. Cushman WC, Brady WE, Gazdick LP, et al. The effect of a losartan- based treatment regimen on isolated systolic hypertension. J Clin Hypertens (Greenwich). 2002;4:101-107.
47. Benedict CR. Safe and effective management of hypertension with fixed-dose combination therapy: focus on losartan plus hydrochlorothiazide. Inf J Clin Pract. 2000;54:48-54.
48. Chrysant SG. Fixed combination therapy of hypertension: focus on val- sartan/hydrochlorothiazide combination (Diovan/HCT). Expert Rev Cardio- vasc Trier. 2003; 1:335-343.
49. Bohm M, Sachse A. Safety and tolerability of eprosartan in combination with hydrochlorothiazide. Drug Sat. 2002:25:599-611.
50. Chrysant SG, Chrysant GS. Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Opin Pharmacother. 2004:5:657667.